Overview

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy before a donor bone marrow stem cell transplant helps stop the growth of cancer cells. Chemotherapy and antithymocyte globulin stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and methotrexate after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well giving donor stem cell transplant together with busulfan, fludarabine, and antithymocyte globulin works in treating patients with hematological cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Treatments:
Antilymphocyte Serum
Busulfan
Calcium
Fludarabine
Fludarabine phosphate
Leucovorin
Levoleucovorin
Methotrexate